Page last updated: 2024-11-06

temelastine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Temelastine is a histamine H1 receptor antagonist with anti-inflammatory and anti-allergic properties. It is used in the treatment of allergic rhinitis, urticaria, and other allergic conditions. Temelastine is thought to exert its effects by blocking the binding of histamine to H1 receptors on cells, thereby preventing the release of inflammatory mediators such as leukotrienes and prostaglandins. The synthesis of temelastine involves several steps, including the reaction of a substituted benzhydryl chloride with an appropriate amine. Temelastine has been studied for its potential therapeutic benefits in a variety of conditions, including allergic rhinitis, urticaria, asthma, and eczema. Its efficacy in these conditions has been supported by several clinical trials. Temelastine is a relatively safe drug with a low incidence of adverse effects. The most common side effects are drowsiness, headache, and dry mouth. Temelastine is generally well-tolerated, although it may interact with other medications. Temelastine is available in several countries around the world. It is marketed under a variety of trade names, including Teldane, Telfast, and Himat.'

Cross-References

ID SourceID
PubMed CID55482
CHEMBL ID70598
CHEBI ID180882
SCHEMBL ID18882
MeSH IDM0140770

Synonyms (33)

Synonym
CHEBI:180882
2-[4-(5-bromo-3-methylpyridin-2-yl)butylamino]-5-[(6-methylpyridin-3-yl)methyl]-1h-pyrimidin-6-one
sk&f-93944
PDSP2_000119
temelastine (usan/inn)
86181-42-2
D06063
temelastine
temelastinum [latin]
sk&f 93944
temelastina [spanish]
2-((4-(5-bromo-3-methyl-2-pyridyl)butyl)amino)-5-((6-methyl-3-pyridyl)methyl)-4(1h)-pyrimidinone
4(1h)-pyrimidinone, 2-((4-(5-bromo-3-methyl-2-pyridinyl)butyl)amino)-5-((6-methyl-3-pyridinyl)methyl)-
PDSP1_000119
CHEMBL70598
L000593
unii-bf6igi53xh
temelastinum
temelastine [usan:inn:ban]
bf6igi53xh ,
temelastina
cas_86181-42-2
bdbm84646
nsc_55482
temelastine [usan]
temelastine [inn]
2-((4-(5-bromo-3-methyl-2-pyridinyl)butyl)amino)-5-((6-methyl-3-pyridinyl)methyl)-4(1h)-pyrimidinone
temelastine [mart.]
SCHEMBL18882
OGEAASSLWZDQBM-UHFFFAOYSA-N
2-[4-(5-bromo-3-methylpyrid-2-yl)-butylamino]-5-(6-methylpyrid-3-yl-methyl)-4-pyrimidone
DTXSID60235437
Q27274634

Research Excerpts

Overview

Temelastine (SK&F 93944) is a novel histamine H1-receptor antagonist. It has a high degree of protein binding and predominant hepatic elimination.

ExcerptReferenceRelevance
"Temelastine is a selective, competitive histamine H1-receptor antagonist which does not penetrate the central nervous system. "( Temelastine, a new H1-receptor antagonist.
Alexander, F; Allison, N; Dubb, JW; Familiar, RG; Stote, RM; Tatoian, D, 1986
)
3.16
"Temelastine (SK&F 93944) is a novel histamine H1-receptor antagonist with a high degree of protein binding and predominant hepatic elimination. "( Temelastine, a novel histamine H1-receptor antagonist, does not induce oxidative hepatic enzyme activity in man.
de Mey, C; Meineke, I; Wesche, H,
)
3.02

Treatment

ExcerptReferenceRelevance
"Rats treated with temelastine (SK&F 93,944), a novel histamine H1-receptor antagonist, develop thyroid lesions characterized by hypertrophy and colloid depletion. "( In vivo biliary excretion and in vitro cellular accumulation of thyroxine by rats or cultured rat hepatocytes treated with a novel histamine H1-receptor antagonist.
Catto, L; Jones, RB; Leonard, T; Poole, A; Pritchard, D, 1990
)
0.61

Dosage Studied

The effectiveness of chronic dosing with temelastine (SK&F 93944) 75 mg twice daily and terfenadine 60 mg twicedaily compared with placebo was assessed using non-invasive objective assessment techniques. The pharmacokinetics of antipyrine were assessed in eight male normal subjects.

ExcerptRelevanceReference
" The inhibition of wheal size was maximal by 2 hr after dosing and was present at 8 hr."( Temelastine, a new H1-receptor antagonist.
Alexander, F; Allison, N; Dubb, JW; Familiar, RG; Stote, RM; Tatoian, D, 1986
)
1.71
" In anaesthetized guinea-pigs SK&F 93944 displaced histamine bronchoconstriction dose-response curves at doses which had negligible effects on histamine tachycardia."( Pharmacological studies with SK&F 93944 (temelastine), a novel histamine H1-receptor antagonist with negligible ability to penetrate the central nervous system.
Brown, EA; Griffiths, R; Harvey, CA; Owen, DA, 1986
)
0.54
" The pharmacokinetics of antipyrine were assessed in eight male normal subjects after single oral doses of 10 mg/kg antipyrine, administered prior to chronic dosing with temelastine 100 mg twice daily for 2 weeks, and 48 hours after the last dose of temelastine."( Temelastine, a novel histamine H1-receptor antagonist, does not induce oxidative hepatic enzyme activity in man.
de Mey, C; Meineke, I; Wesche, H,
)
1.77
" The effectiveness of chronic dosing with temelastine (SK&F 93944) 75 mg twice daily and terfenadine 60 mg twice daily compared with placebo in inhibiting the weal and flare response to intradermal histamine was assessed using non-invasive objective assessment techniques."( Non-invasive instrumental techniques to detect terfenadine and temelastine induced suppression of histamine weals in man.
Marks, R; Shall, L, 1987
)
0.78
" In the PAG/DR, the HA dose-response curve had an inverted U-shape, showing that HA can induce both antinociceptive (0."( Histamine-induced modulation of nociceptive responses.
Hough, LB; Mischler, SA; Nalwalk, JW; Thoburn, KK, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyrimidoneA pyrimidine carrying one or more oxo substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Temelastine H1-Antihistamine Action87

Bioassays (2)

Assay IDTitleYearJournalArticle
AID135327BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (66.67)18.7374
1990's7 (25.93)18.2507
2000's2 (7.41)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]